We use cookies to make this site work. We'd also like to set optional cookies so we can understand how the site is used and improve it. We will not set optional cookies unless you accept them. You can change your choice at any time from the Cookie settings link in the footer.
Strictly necessary cookies
These cookies are required for the site to work. They store your cookie preferences and keep your session secure. They are exempt from consent under PECR Regulation 6(4) because they are essential to deliver the service you have requested.
Optional cookies
Optional cookies help us understand how the site is used and provide additional features such as analytics, accessibility tools and translation. We will only set them if you accept.
Access to tirzepatide (Mounjaro) through primary care
For managing overweight and obesity
As you will be aware, NHS England is making tirzepatide (Mounjaro) available in a phased approached over the next few years. NICE guidelines say that in order to gain access to tirzepatide (Mounjaro) on the NHS, patients must also be referred on to a diet and exercise support programme.
Although it has been announced that it will become available in primary care settings from Monday, 23 June (for a specific patient cohort) arrangements are being made to mobilise a provider of the necessary Behavioural Support for Obesity Prescribing (BSOP) that is specified in the NICE guidelines.
Until this service is in place in Kent and Medway, it is not possible to prescribe tirzepatide (Mounjaro) in primary care.
Please also note there is no provider of tirzepatide (Mounjaro) available under right to choose.
We are aware that this situation may be difficult for practices to explain to patients. If you are approached, NHS England has produced answers to some frequently asked questions for patients.
We will provide further information when it is available.
Published: Jun 23, 2025